Clinical Trial

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

Study acronym: DANNOAC-VTE
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in venous thromboembolism across Danish hospitals.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-04-21; most recent amendment 2025-05-14.
Status change: Recruiting → Active, Not Recruiting 2025-05-14
Status change: Not Yet Recruiting → Recruiting 2023-07-05
Status change: Recruiting → Not Yet Recruiting 2023-04-02
Status change: Not Yet Recruiting → Recruiting 2017-04-30
Trial Details
NCT Number NCT03129555
Lead Sponsor Herlev and Gentofte Hospital
Conditions Deep Vein Thrombosis, Pulmonary Embolism
Enrollment 5,000 participants
Start Date 2023-04-01
Primary Completion 2027-03-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-15